Nucleotide-based Pathogen Treatment Systems for Water, Agriculture, and Surfaces

Publication ID: 24-11857560_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Nucleotide-based Pathogen Treatment Systems for Water, Agriculture, and Surfaces,” Published Technical Disclosure No. 24-11857560_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857560_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,560.

Summary of the Inventive Concept

This inventive concept expands the application of nucleotide and nucleoside compositions to treat waterborne pathogens, agricultural pathogens, and surface pathogens, leveraging the core technology of the original patent to address critical problems in these new fields.

Background and Problem Solved

The original patent disclosed pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections. However, the growing concern about waterborne, agricultural, and surface pathogens necessitates innovative solutions. The new inventive concept addresses these pressing issues by adapting the core technology to develop nucleotide-based treatment systems for these new applications.

Detailed Description of the Inventive Concept

The inventive concept involves the use of nucleotide or nucleoside compositions of Formula Im, wherein R1 is:, R2 is alkyl or cycloalkyl, and R3 is aryl, wherein the aryl is optionally substituted with one or more substituents. These compositions can be applied to water treatment systems to reduce the concentration of waterborne pathogens, to crops to reduce the concentration of agricultural pathogens, or to surfaces to reduce the concentration of pathogens. The compositions can be prepared using various methods, including conjugation with amino acid esters, lipids, or sphingolipids, and can be formulated with pharmaceutically acceptable excipients.

Novelty and Inventive Step

The new claims introduce a novel application of the nucleotide and nucleoside compositions, extending their use beyond pharmaceutical compositions for treating viral infections to treating waterborne, agricultural, and surface pathogens. The inventive step lies in the recognition of the potential of these compositions to address critical problems in these new fields and the adaptation of the core technology to develop effective treatment systems.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different nucleotide or nucleoside compositions, varying the type and amount of substituents, or modifying the formulation to enhance efficacy or stability. Additionally, the treatment systems could be integrated with existing infrastructure, such as water treatment plants or agricultural irrigation systems, to enhance their effectiveness.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the water treatment, agriculture, and surface disinfection industries, where the need for effective pathogen treatment solutions is pressing. The market for these solutions is substantial, with potential applications in municipal water treatment, agricultural crop protection, and surface disinfection for healthcare and food processing facilities.

Field of Art

Pharmaceutical chemistry, specifically nucleotide and nucleoside composition design for pathogen treatment, with expertise in molecular conjugation, formulation techniques, and application strategies across biological systems

Person of Ordinary Skill (PHOSITA) Profile

A PhD-level researcher with advanced training in organic chemistry, molecular biology, and pharmaceutical sciences, capable of understanding complex molecular structures, designing chemical variations, and evaluating potential applications across different treatment domains

Obviousness Rationale

A PHOSITA would recognize that the fundamental nucleotide composition from the source patent provides a versatile molecular platform that can be readily adapted to different pathogen treatment contexts. The core chemical structure remains substantially unchanged, with the primary innovation being the expanded application domains of water, agricultural, and surface pathogen treatment. The molecular mechanisms of nucleotide interactions with biological systems suggest predictable efficacy across different environmental contexts.

Obvious Combinations & Variations

Source Patent Element
Pharmaceutical compositions with sulfur-containing nucleosides conjugated to phosphorus oxide
PTD Variation
Applying the same nucleoside compositions to water, agricultural, and surface pathogen treatment systems
Obviousness Reasoning
Known molecular mechanisms of nucleotide interactions with pathogens suggest transferable antimicrobial properties across different environmental contexts, representing a predictable extension of the original technological concept
Source Patent Element
Conjugation methods involving amino acid esters, lipids, and sphingolipids
PTD Variation
Adapting conjugation techniques to enhance stability and efficacy in water treatment, crop protection, and surface disinfection applications
Obviousness Reasoning
Conjugation strategies are well-established techniques in pharmaceutical chemistry, and a PHOSITA would recognize the potential for modifying delivery mechanisms to suit different treatment environments
Source Patent Element
Pharmaceutical composition with specific R1, R2, and R3 substituent configurations
PTD Variation
Maintaining identical molecular structure while expanding application domains beyond viral infection treatment
Obviousness Reasoning
The molecular structure remains consistent, indicating that the primary innovation is the recognition of broader application potential rather than fundamental chemical redesign
Source Patent Element
Use of pharmaceutically acceptable excipients like glucose, gum arabic, and lactose
PTD Variation
Adapting excipient formulations to optimize stability and efficacy in water, agricultural, and surface treatment systems
Obviousness Reasoning
Formulation optimization is a standard practice for a PHOSITA, representing a routine engineering task to extend technological applicability
Source Patent Element
Viral infection treatment using nucleotide compositions
PTD Variation
Expanding pathogen treatment to waterborne, agricultural, and surface contexts
Obviousness Reasoning
The broad antimicrobial potential of nucleotide compositions suggests predictable efficacy across different pathogen interaction scenarios, representing an obvious technological extension
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857560, a Person Having Ordinary Skill In The Art would find the variations disclosed in the Published Technical Disclosure to be obvious extensions of the prior art, as the fundamental molecular structure remains unchanged and the application of nucleotide compositions to alternative pathogen treatment domains represents a predictable and routine technological adaptation within the state of the art.

Original Patent Information

Patent NumberUS 11,857,560
TitlePharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections
Assignee(s)Emory University